Symposium on muscleMuscular dystrophy: Review and recent observations☆
References (84)
- et al.
Activités enzymatiques du muscle humain
Clin. chim. acta
(1956) - et al.
Determination of aldolase in animal tissues
J. Biol. Chem.
(1949) - et al.
Formation of the sex chromatin by a single X-chromosome in liver cells of
Rattus norvegicus. Exper. Cell Res.
(1959) Clinical manifestations in two carriers of Duchenne muscular dystrophy
Lancet
(1963)- et al.
The characterization of adult human myoglobin
J. Biol. Chem.
(1962) - et al.
Genetics and diseases of muscle
Am. J. Med.
(1963) - et al.
The ontogeny of isozyme patterns of lactate dehydrogenase in the mouse
Devel. Biol.
(1962) - et al.
On the classification, natural history and treatment of the myopathies
Brain
(1954) A biochemical approach to genetics
Clinical aspects of human muscular dystrophy
Neue Ergebnisse der Genetik der Muskeldystrophien
Acta genet. med. et. gemel
Two new families of benign sex-linked recessive muscular dystrophy
Rev. canad. de Biol.
Diseases of Muscle: A Study in Pathology
Hereditary nonprogressive muscular dystrophy inducing arthrogryposis syndrome
Brain
Progressive dystrophy of external ocular muscles (ocular myopathy)
Brain
Myopathia distalis tarda hereditaria
Acta med. scandinav.
Pathology of human muscular dystrophy
Progressive muscular dystrophy: the histopathological changes in skeletal muscle obtained by biopsy
J. Path. & Bact.
Serum enzymes in muscular dystrophy and certain other muscular and neuromuscular diseases. I. Serum glutamic oxalacetic transaminase
New England J. Med
Serum enzymes and genetic carriers in muscular dystrophy
Am. J. Human Genet.
Histopathological features of muscle in the preclinical stages of muscular dystrophy
Brain
Studies of enzymes in serum in muscular dystrophy. II. Diagnostic and prognostic significance in relatives of dystrophic persons
Pediatrics
Biochemistry of Hereditary Myopathies
Biochemistry of progressive muscular dystrophy
A biochemical study of certain skeletal muscle constituents in human progressive muscular dystrophy
J. Clin. Invest.
Muscular dystrophy: quantitative studies on the composition of dystrophic muscle
Res. Publ., A. Nerv. & Ment. Dis.
Factors regulating the creatinine output in man
Am. J. Physiol.
Studies of diseases in muscle. I. Metabolism of creatine and creatinine in progressive muscular dystrophy
Arch. Neurol. & Psychiat.
Serum enzymes in the pathophysiology of muscle
Ann. New York Acad. Sc.
Aminoaciduria in progressive muscular dystrophy
Rev. canad. de Biol.
L'élévation du taux de Paldolase sérique, test biochemique des myopathies
Semaine hôp. Paris
Serum enzyme activity in muscular dystrophy
Brit. M. J.
High creatine phosphokinase activity of sera of progressive muscular dystrophy
J. Biochem.(Tokyo)
Étude de la créatine-kinase sérique chez les myopathes et leurs familles
Rev. Franc. Étud. clin. biol.
Serum creatine phosphokinase activity in progressive muscular dystrophy and neuromuscular diseases
Arch. Neurol.
Biochemical and histological features of early muscular dystrophy
Rev. canad. de Biol.
Serum enzyme studies in muscular dystrophy. III. Serum malic dehydrogenase, 5-nucleotidase and adenosinetri-phosphatase
Étude de l'aldolase et de la créatine kinase du serum chez les mères de myopathies
Rev. Franc. Étud. clin. biol.
Progressive muscular dystrophy. II. Biochemical identification of the carrier state in recessive sex-linked juvenile (Duchenne) type by serum creatine-phosphokinase determinations
Enzymol. biol. clin.
Progressive muscular dystrophy. V. The identification of the carrier state in the Duchenne type by serum creatine kinase determination
Am. J. Human Genet.
Serum enzymes in carriers of muscular dystrophy
Brit. M. J.
Cited by (34)
Combining passive leg-lifting with transmural myocardial strain profile for enhanced predictive capability for subclinical left ventricular dysfunction in Duchenne muscular dystrophy
2015, Journal of CardiologyCitation Excerpt :Since subclinical LV myocardial dysfunction may develop and progress early in life, the early detection of this abnormality in DMD patients when their LVEF remains preserved is important because medical treatment can be administered earlier, and is therefore vital for prevention of the development of myocardial fibrosis [19,20]. Fibrotic changes, however, do not always occur homogeneously in the heart and cardiac fibrosis in DMD patients begins in the outer half of the myocardium, especially in the LV posterior wall [21,22]. Moreover, early detection of subclinical LV dysfunction in DMD patients with preserved LVEF can be challenging [23].
Utility of transmural myocardial strain profile for prediction of early left ventricular dysfunction in patients with Duchenne muscular dystrophy
2013, American Journal of CardiologyCitation Excerpt :The cardiac involvement caused by DMD progresses toward cardiomyopathy with dilation of the chambers and suppression of LV function and is responsible for death in approximately 40% of patients aged 10 to 30 years.11–15 Histologic changes in the heart of patients with DMD have been identified as fibrosis, degeneration, and fatty infiltration.16,17 Fibrotic changes, however, do not always occur homogeneously in the heart and cardiac fibrosis in patients DMD begins in the outer ½ of the myocardium, especially in the LV posterior wall.16,17
Peak negative myocardial velocity gradient and wall-thickening velocity during early diastole are noninvasive parameters of left ventricular diastolic function in patients with Duchenne's progressive muscular dystrophy
2004, Journal of the American Society of EchocardiographyThe heart in neuromuscular disease
1986, Current Problems in CardiologySequential changes of orthogonal electrocardiograms in progressive muscular dystrophy of the Duchenne type
1979, American Heart JournalSerum pyruvate-kinase (PK) and creatine-phosphokinase (CPK) in progressive muscular dystrophies
1978, Journal of the Neurological Sciences
- ☆
Parts of this study were supported by grants from the Muscular Dystrophy Associations of America.
- 1
From the Department of Medicine, U.C.L.A. Center for the Health Sciences and Wadsworth Hospital, Veterans Administration Center, Los Angeles, California.